Collegium Pharmaceutical is a U.S.-focused specialty biopharma company that sells branded prescription drugs for chronic pain and ADHD. The pain portfolio — Belbuca, Xtampza ER, and the Nucynta franchise — treats adults with moderate to severe chronic or acute pain and collectively represents roughly half of the branded extended-release opioid market in the U.S. Each product is differentiated: Belbuca is the only long-acting opioid using buprenorphine buccal film technology; Xtampza ER is the only extended-release oxycodone using Collegium's proprietary DETERx abuse-deterrent microsphere technology; and the Nucynta products are tapentadol formulations licensed from Grünenthal. In ADHD, Collegium sells Jornay PM, a methylphenidate stimulant with a unique evening dosing mechanism that delivers symptom control from waking through the day — the only FDA-approved stimulant with this profile. Collegium sells through wholesalers to retail pharmacies, managed care organizations, and government agencies, supported by two dedicated field sales forces. Revenue is driven by prescription volume and gross-to-net dynamics, where payer rebates and formulary positioning meaningfully affect net revenue per prescription. The pain portfolio (~80% of revenue) is a mature, high-margin cash generator, while Jornay (~20% of revenue) is the growth driver. Collegium uses pain cash flows to fund Jornay's commercialization, repay debt, and buy back shares. On M&A, Collegium targets commercial-stage CNS, pain-adjacent, or rare disease assets.